Leukoplakia Lesions Respond to Soy Protease Inhibitor A soy-derived protease inhibitor appears to shrink precancerous oral lesions. In a phase-1 study, the size of leukoplakia lesions shrank in 10 of 32 patients (31%) taking various doses of Bowman-Birk inhibitor concentrate daily for a month, reported Dr. Frank L. Meyskens Jr. of the University of California Irvine and colleagues in the December Clinical Cancer Research. Two were complete responses, and eight were partial responses with a decrease in lesion area of more than 50%. Across all dose levels there was a 24.2% average decrease in lesion area. Among 75 individual lesions, 58.7% decreased in size, 14.7% stayed the same, and 26.7% grew during treatment. There was no dose-limiting toxicity. Three patients had grade-1 nausea, diarrhea, and epigastric pain, and researchers found response to the agent to be dose-related. The researchers said that BBIC's mechanism is unknown. Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.